stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Net income
Revolution Medicines, Inc.'s net income for fiscal 2025 was −$1.1B, compared with −$600.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.9B. Over the past ten years it has ranged from −$1.1B (fiscal 2025) to −$31.1M (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 8 consecutive fiscal years. Revolution Medicines, Inc. ranks 604th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$1.1B | — |
| FY2024 | −$600.1M | — |
| FY2023 | −$436.4M | — |
| FY2022 | −$248.7M | — |
| FY2021 | −$187.1M | — |
| FY2020 | −$108.2M | — |
| FY2019 | −$47.7M | — |
| FY2018 | −$41.8M | — |
| FY2017 | −$31.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$407.5M | — |
| Jun 2026 | −$644.4M | — |
| Mar 2026 | −$453.8M | — |
| Dec 2025 | −$364.9M | — |
| 29 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $915.6M |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
| RVMD Revolution Medicines, Inc. | −$1.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RVMD
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement